Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Nemolizumab may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for What Nemluvio is Nemluvio contains the active substance nemolizumab. Nemolizumab is a monoclonal antibody (a type of specialised protein) that blocks the action of proteins called interleukin (IL)-31. IL-31 plays a major role in causing the signs and symptoms of atopic dermatitis and prurigo nodularis. What Nemluvio is used for Nemluvio is used to treat adults and patients 12 years of age and older, weighing at least 30 kg, with moderate to severe atopic dermatitis (also known as atopic eczema) who can be treated with systemic treatments (a medicine given by mouth or injection). Nemluvio can be used with certain topical eczema medicines. Nemluvio is also used to treat prurigo nodularis (PN), also known as chronic nodular prurigo (CNPG). How Nemluvio works Using Nemluvio for atopic dermatitis or prurigo nodularis can improve the condition of your skin and reduce symptoms including itching and sleep disturbance. In addition, Nemluvio helps improve symptoms related to pain and overall quality of life from your atopic dermatitis or prurigo nodularis.
2. What you need to know before you use Nemluvio
Other medicines and Nemluvio Tell your doctor or pharmacist
3. How to use Nemluvio Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
e
Step 1: Let Nemluvio reach room temperature
Nemluvio pre-filled dual-chamber pen
After use Grey cap
Needle cover Orange needle guard Grey rod
Lyophilized Powder (medicine)
Orange rod
Activation knob (arrow on locked icon)
Let Nemluvio come to room temperature.
not: ! Do
wave, direct sunlight). This might damage Nemluvio.
Step 2: Wash your hands a. To avoid contamination and infection, wash your hands with soap (see Figure B). b. Dry them properly.
Step 3: Gather Supplies (see Figure C) a. Remove the pen from the carton. b. Gather the following supplies on a clean, flat and well-lit surface: Figure C 1. 2. 3. 1. Pen 2. Alcohol wipes* 3. Sharps disposal container* 4. Gauze pads or cotton balls* *Items not included in the carton.
4.
Note: In some cases, your doctor will prescribe two pens. Use one pen after the other.
Step 4: Check the Nemluvio pen for the following: a. Expiration date has not passed.
Figure D
b. The lyophilized powder is white and not dissolved (see Figure D).
!
Inspection window
Water for dissolving the medicine (in a separate chamber, not visible)
30- 45
minutes
Lyophilized powder Expiration date
c. The pen has not been dropped and is not damaged or cracked.
Device Overview Before use
Injecting cold medicine might result in pain at the injection site. Take the Nemluvio carton out of the refrigerator and let it come to room temperature for 30 to 45 minutes before starting Step 2 (see Figure A).
Figure A
It is normal that orange rod does not cover the full window at the end of the injection
Activation knob (arrow on unlocked icon)
Do not use the pen unless all conditions above are met. If any condition is not met, throw away the pen and use a new one (see Section C: "Throwing away Nemluvio").
Step 5: Activate the Nemluvio pen Hold the pen upright and turn the activation knob to the right until it stops (see Figure E). This starts the process of transferring water to the powder chamber.
Unlock Icon
Figure E
Turn over to continue reading about the pen injection steps and FAQs
13/01/26 12:07
A. Preparing to inject Nemluvio
B. Injecting Nemluvio
Step 6: Wait until grey rod stops moving
Step 10: Select one injection site
Watch inspection window until grey rod has stopped moving (see Figure F).
Figure F
(see Figure J)
When using a second pen, select a different injection site at least 2.5 cm away from the first injection site. Select the injection site using the following chart:
Grey rod Before After
!
C. Throwing away Nemluvio
Self-Injection
Do not shake the pen before the grey rod has completely stopped. You might get an incorrect dose of medicine.
Figure J Injection by Caregiver
Step 7: Shake to dissolve the medicine When the grey rod has completely stopped, shake the pen up and down for 30 seconds (see Figure G).
30
seconds
Shake for 30 seconds Figure G
Step 8: Wait 5 minutes for bubbles to decrease Wait for bubbles to decrease and the lyophilized powder to dissolve completely. This will take about 5 minutes (see Figure H).
Wait 5
minutes Not dissolved
Dissolved
Note: If the medicine has not dissolved completely, shake again for 30 seconds and then wait 5 minutes. Note: It is normal for a small foam layer or a few small air bubbles to remain in the dissolved medicine.
Step 9: Check the medicine in the inspection window Check to see if the dissolved medicine: a. is clear and colourless to slightly yellow, b. does not contain particles. (see Figure i).
Dissolved Figure i
!
Do not use the pen if the dissolved medicine is cloudy or contains any particles. Throw away the pen and use a new one (see Section C:"Throwing away Nemluvio").
Note: After the medicine has dissolved, it must be used within 4 hours. During this time, it should be kept at room temperature (up to 25°C). If you have not used it within 4 hours, throw it away.
(085294) P202913-0 NEMO PEN IFU – UK.indd 2
Step 11: Clean the injection site
Gently push the pen down Orange rod until orange needle guard is completely pushed in. The injection starts right away with a click (see Figure N).
!
Figure K
Alcohol Wipe
Do not:
Do not:
a. Hold the pen upright (see Figure L, a). b. Unscrew the grey cap until the orange needle Do not pull guard pops up (see the grey cap Figure L, b). c. Gently pull the cap off a b c the orange needle guard (see Figure L, c). d. After cap removal, please throw away the cap in a sharps disposal container (see Step 17). Hold Unscrew Pull off Note: If the cap cannot upright cap cap be removed, refer back Figure L (a,b,c) to Step 5 and make sure activation knob is turned completely to the right until it stops.
click! Start injection
Push down on the orange needle guard
Do not lift the pen yet and keep pushing down.
Hold and slowly count to 15.
Orange rod
Check inspection window to make sure orange rod and grey rod have stopped Grey rod (see Figure O). This means the injection has been completed.
Figure O
15
seconds
Hold and slowly count to 15.
Note: It is normal that the orange rod does not cover the whole inspection window at the end of injection.
!
Do not lift pen until orange rod and grey rod have stopped moving.
If the orange rod is not visible please throw away the pen and use a new one (see Section C:"Throwing away Nemluvio").
Step 16: Lift the Nemluvio pen up Figure P a. Lift the pen straight up from your skin. Lift The orange needle straight guard locks into place up to cover the needle (see Figure P). b. If there is bleeding, press a cotton ball or Orange gauze over the needle guard injection site.
Avoid contact with the needle.
Pen
Grey cap
Throw away the used pen and the grey cap in a sharps disposal container right away after use (see Figure Q).
Needle Where is the needle? The needle is attached to the Nemluvio pen and covered by the grey cap. When you twist the grey cap, the orange needle guard pops up and keeps the needle covered until you inject. For more information, please see the figures in Step 12 in the Instructions for Use.
Dissolving the medicine Figure Q
!
Figure N
Grey rod
Step 15: Inject for 15 seconds
Step 12: Twist the grey cap
!
Figure M Note: Always inject the way your healthcare professional showed you. Place the pen on the injection site vertically so that the orange needle guard is flat against the skin (see Figure M). Note: Make sure you can Orange easily see the inspection needle Injection guard window during injection. site
!
(see Figure K)
!
Read Steps 13-16 before starting Step 13.
Step 14: Start injection and hold the Nemluvio pen on the skin
Where not to inject: Near your waistline or about 5 cm around the navel. Into tender, bruised, red skin, or areas with scars or stretch marks. Twice into the same site (for example, within 2.5 cm).
a. Always use a new alcohol wipe to clean the injection site. This avoids contamination and infection. b. Let the skin air dry.
Figure H
Step 17: Throw away the pen and the cap
Step 13: Place the Nemluvio pen
!
FAQs (Frequently asked questions)
Do not:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local laws about how you should throw away used pens.
How do I know if the medicine is fully dissolved? To dissolve, shake the Nemluvio pen up and down until the white particles are no longer on the bottom, top, or sides. The dissolved medicine should look clear. Please refer to Step 9 in the Instructions for Use. After shaking the Nemluvio pen, look through both sides of the inspection window. You should not see any white particles along the bottom, top, or sides. It is acceptable to have small air bubbles or a small foam layer on top of the medicine. It does not harm you. If you see white particles in the medicine, it is not fully dissolved.
Storage How should I store the Nemluvio pen? The Nemluvio pen should be stored in the refrigerator. It can be stored at room temperature up to 25°C for a single period of up to 90 days. The device should not come in contact with liquids.
Where do I find the expiration date? You can find the expiration date on the pen, it is labeled EXP MM/YYYY. Do not use the Nemluvio pen past the expiration date.
What should I do if the medicine has been frozen?
Injecting the medicine Why do I need to hold the pen upright while removing the grey cap? Holding the Nemluvio pen with the grey cap upright helps prevent the medicine from leaking. It is normal to see a few drops of medicine inside the grey cap even when you hold the pen upright and remove the grey cap.
How do I know I injected myself the full content of the pen? To be sure you get the full content, press and hold the Nemluvio pen against your skin. You will feel the needle go into your skin. Hold the Nemluvio pen against your skin for 15 seconds. This will allow enough time for all the medicine to go from the pen to under your skin. Only remove the Nemluvio pen when the orange rod and the grey rod have stopped moving. After removing the Nemluvio pen, look for the orange rod in the window as a way to tell that the content has been given. If the orange rod does not appear, throw away the pen and use a new one. For details please refer to Step 15 in the Instructions for Use.
General Information Is it necessary to receive instructions on how to use the Nemluvio pen from a healthcare professional? Yes. Do not inject the medicine if you did not receive a demonstration by your healthcare professional. You should contact your healthcare professional to receive the information on how to use the Nemluvio pen.
Where can I get more information about using Nemluvio: Call your healthcare professional.
Do not use the Nemluvio pen if it has been frozen. Throw away the Nemluvio pen and use a new one.
locked
!
Do not rub the injection site.
13/01/26 12:07
and for how long Your doctor will decide how much Nemluvio you need and how long you will use it for. Recommended dose in adults and adolescents patients with atopic dermatitis (12 years of age and older) For patients with atopic dermatitis, the recommended dose of Nemluvio is:
Subsequent doses
less than 90 kg 60 mg (two 30 mg injections)
30 mg every 4 weeks
90 kg or more
60 mg (two 30 mg injections) every 4 weeks
60 mg (two 30 mg injections)
Injecting Nemluvio Nemluvio is given as an injection under your skin (subcutaneous injection) into the front upper thigh or abdomen, avoiding a 5 cm area around the navel. If somebody else gives the injection, it can also be given into the upper arm. You and your doctor or nurse will decide if you can inject Nemluvio yourself. It is recommended that you change the injection site with each injection. Nemluvio should not be injected into skin that is tender, inflamed, swollen, damaged or has bruises, scars or open wounds. Before injecting Nemluvio yourself, you must have received proper instruction by a doctor or nurse. Your Nemluvio injection may also be given by a caregiver after proper instruction by a doctor or nurse. The pre-filled pen must not be shaken. Read carefully the instructions for use included at the end of this package leaflet before using Nemluvio. If you use more Nemluvio than you should If you use more Nemluvio than you should or the dose has been given too early, talk to your doctor, pharmacist or nurse. If you forget to use Nemluvio If you have forgotten to inject a dose of Nemluvio, talk to your doctor, pharmacist or nurse. Give the Nemluvio injection as soon as possible, then continue with your original schedule. If you stop using Nemluvio Do not stop using Nemluvio without speaking to your doctor first. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
P202913-0
Do not use Nemluvio
population. Like all medicines, this medicine can cause side effects,
(085294) P202913-0 NEMO PEN IFU – UK.indd 1
Nemluvio Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2°C to 8°C). Do not freeze. Store in the original carton in order to protect from light. If necessary, Nemluvio may be kept at room temperature (up to 25°C) for a single period of up to 90 days. Write the date first removed from the refrigerator in the space provided on the outer carton for the pen. Do not use Nemluvio beyond the expiration date or 90 days after the date it was first removed from the refrigerator (whichever is earlier). Do not use this medicine if you notice that the powder is not white. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Nemluvio contains
INSTRUCTIONS FOR USE CAREFULLY read and follow Instructions for Use. This pen requires specific steps before injection.
®
30 mg
powder and solvent for solution for injection in pre-filled pen
nemolizumab
These "Instructions for Use" contain information on how to inject Nemluvio. Read and understand these instructions before using the Nemluvio pen. Do not inject yourself or someone else until you have been instructed how to inject Nemluvio. In adolescents (ages 12 to 17 years old), it is recommended that Nemluvio be given by or under supervision of a trained adult or caregiver. Your healthcare professional will instruct you or your caregiver on how to prepare and inject a dose of Nemluvio before you try to do it yourself the first time. Call your healthcare professional if you have any questions. Nemluvio is supplied as a single-use, prefilled dual-chamber pen (called "Nemluvio pen" or "pen" in these instructions). It contains medicine (30 mg of lyophilized powder) in one chamber and water for dissolving the medicine in the other chamber. Before you inject it, you must mix the lyophilized powder with the water for dissolving the medicine.
Important Information
A. Preparing to inject Nemluvio
Nemluvio 30 mg powder and solvent for solution for injection in pre-filled pen comes as injection containing 30mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Nemluvio 30 mg powder and solvent for solution for injection in pre-filled pen is nemolizumab.
This leaflet reproduces the patient information leaflet approved for Nemluvio 30 mg powder and solvent for solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Atopic dermatitis (AD)
Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy.
Prurigo nodularis (PN)
Nemluvio is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
Posology
Atopic dermatitis (AD)
The recommended dosage of Nemluvio is:
- An initial dose of 60 mg (two 30 mg injections), followed by 30 mg given every 4 weeks (Q4W)
- After 16 weeks of treatment, for patients who achieve clinical response, the recommended maintenance dose of Nemluvio is 30 mg every 8 weeks (Q8W).
Concomitant Topical Therapies:
Use Nemluvio with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies.
Consideration should be given to discontinuing treatment with Nemluvio in patients who have shown no response after 16 weeks of treatment.
Prurigo nodularis (PN)
The recommended dose of Nemluvio for patients weighing < 90 kg is an initial dose of 60 mg (two 30 mg injections), followed by 30 mg given every 4 weeks (Q4W).
The recommended dose of Nemluvio for patients weighing ≥ 90 kg is an initial dose of 60 mg dose (two 30 mg injections), followed by 60 mg given every 4 weeks (Q4W).
Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment for prurigo nodularis.
Missed dose
If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.
Special populations
Elderly (≥ 65 years)
No dose adjustment is recommended for elderly patients (see section 5.2).
Hepatic and Renal impairment
No dose adjustment is needed in patients with hepatic or renal impairment (see section 5.2).
Body weight
No dose adjustment for body weight is recommended for patients 12 years of age and older with atopic dermatitis (see section 5.2).
For patients with prurigo nodularis and with body weight ≥ 90 kg, the 60 mg dose (two 30 mg injections) is recommended (see section 5.2).
Paediatric population
The safety and efficacy of Nemluvio in children with moderate-to-severe atopic dermatitis younger than 12 years old have not yet been established.
The safety and efficacy of Nemluvio has not been established in patients below the age of 18 years with prurigo nodularis.
Method of administration
Subcutaneous use.
Administer subcutaneous injection into the front upper thighs or abdomen avoiding the 5 cm area around the navel. Injection into the upper arm should only be performed by a caregiver or healthcare professional.
For the initial dose, administer each of the two Nemluvio injections at different injection sites.
For subsequent doses, it is recommended to rotate the injection site with each dose. Nemluvio should not be injected into skin that is tender, inflamed, swollen, damaged or has bruises, scars or open wounds.
Nemluvio is intended for use under the guidance of a healthcare professional. A patient may self-inject Nemluvio or the patient's caregiver may administer Nemluvio if their healthcare professional determines that this is appropriate. Prior to first injection, patients and/or caregivers should be given proper instructions for preparation and administration of Nemluvio according to the instructions for use at the end of the package leaflet.
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Hypersensitivity
If a systemic hypersensitivity reaction (immediate or delayed) occurs, administration of Nemluvio should be discontinued and appropriate therapy initiated.
Vaccinations
Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with Nemluvio. Avoid use of live vaccines in patients treated with Nemluvio. It is unknown if administration of live vaccines during Nemluvio treatment will impact the safety or efficacy of these vaccines. No data are available on the response to non-live vaccines.
Uncontrolled asthma
Patients with uncontrolled asthma were excluded from the trials and no data with Nemluvio are available in this population.
Interactions with cytochrome P450
The effects of nemolizumab on the pharmacokinetics of midazolam (CYP3A4/5 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate), and caffeine (CYP1A2 substrate) were evaluated in a study (SPR.201593) in 14 subjects with moderate to severe AD receiving an initial subcutaneous dose of 60 mg followed by a 30-mg subcutaneous dose every 4 weeks for 12 weeks. No clinically significant changes in the exposure of CYP450 substrates before and after multiple nemolizumab injections were observed, with Cmax and AUC ratios ranging from 88.24 to 107.81%. An effect of nemolizumab on the PK of co-administered medications is not expected.
Pregnancy
There is a limited amount of data on the use of nemolizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of nemolizumab during pregnancy.
Breast-feeding
No data are present on the excretion of nemolizumab in human milk. In humans, excretion of IgG antibodies in milk occurs during the first few days after birth, which is decreasing to low concentrations soon afterwards. Consequently, transfer of IgG antibodies to the newborns through milk, may happen during the first few days. In this short period, a risk to the breastfed child cannot be excluded. Afterwards, nemolizumab could be used during breast-feeding if clinically needed.
Fertility
Animal studies showed no impairment of fertility (see section 5.3).
Nemluvio has no or negligible influence on the ability to drive and use machines.
Summary of the safety profile
The most common adverse reaction in patients with atopic dermatitis is urticaria. The most common adverse reactions in patients with prurigo nodularis are headache, dermatitis atopic, eczema and eczema nummular.
Uncommon cases of hypersensitivity reactions were reported in both indications (see section 4.4).
Tabulated list of adverse reactions
The Nemluvio safety data presented in Table 1 were evaluated in a pool of three randomized, placebo-controlled trials in subjects with atopic dermatitis (1192 patients receiving Nemluvio and 640 patients receiving placebo), and two randomized, placebo-controlled trials in subjects with prurigo nodularis (370 patients receiving Nemluvio and 186 patients receiving placebo).
Listed in Table 1 are adverse reactions observed in clinical trials presented by system organ class and frequency, using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Table 1: List of adverse reactions
MedDRA System Organ Class
Frequency
Adverse reactions
Nervous system disorders
Common
Headache (incl. tension headache)*
Skin and subcutaneous tissue disorders
Common
Urticaria†
Dermatitis atopic*, Eczema*, Eczema nummular*
Uncommon
Angioedema*
Bullous pemphigoid#
General disorders and administration site conditions
Uncommon
Injection site reactions (includes erythema, pruritus, pain†, irritation†, bruising*)
Rare
Injection site oedema†
†Occurred in atopic dermatitis studies
*Occurred in prurigo nodularis studies
# From post-marketing reporting
In atopic dermatitis, the safety profile of Nemluvio through Week 52 in the open-label trial (ARCADIA LTE) was generally consistent with the safety profile observed at Week 16.
In prurigo nodularis, the safety profile of Nemluvio through Week 52 in the open-label trial (OLYMPIA LTE) was generally consistent with the safety profile observed at Week 16 and at Week 24.
Description of selected adverse reactions
Hypersensitivity
Type 1 hypersensitivity reactions (Ig-E mediated reactions) were reported in patients treated with Nemluvio in atopic dermatitis and prurigo nodularis. These included mild urticaria and one report of mild facial (peri-ocular) angioedema (0.3%) that did not lead to discontinuation of treatment. There were no reports of anaphylactic shock or serum-sickness.
Injections site reactions
The incidence of injection site reactions during the initial period was low in patients with atopic dermatitis treated either with Nemluvio (1.3% subjects) or placebo (1.1% subjects); during the maintenance period, the incidence remained low with Nemluvio Q4W (0.6%), Nemluvio Q8W (0%) and placebo (0.5%).
In patients with prurigo nodularis, the incidence of injection site reactions was low when treated either with Nemluvio (1.1%) or placebo (1.6%). There were no severe injection site reactions.
For both indications, none of the reactions led to discontinuation of treatment.
Headache
In patients with prurigo nodularis, headache was more frequently reported in Nemluvio-treated patients (7.0%) compared to patients treated with placebo (3.6%). Headache was more frequently observed in female patients in both groups. In the Nemluvio group, headache was mostly mild or moderate in severity and did not lead to discontinuation of treatment.
Eczematous reactions
In patients with prurigo nodularis, eczematous reactions such as dermatitis atopic, eczema nummular or eczema were more frequently reported in Nemluvio-treated patients compared to patients treated with placebo: dermatitis atopic (4.6% subjects versus 0.5% subject respectively), eczema (3.8% subjects versus 2.2% subjects respectively) and eczema nummular (3.5% subjects versus 0% subjects respectively). These eczematous reactions were mild or moderate in severity. Dermatitis atopic led to Nemluvio discontinuation in 2 (0.5%) patients. No event of eczema nummular or eczema led to study discontinuation.
Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity with Nemluvio.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the trials described below with the incidence of anti-drug antibodies in other trials, including those of nemolizumab.
Anti-Drug-Antibodies (ADA) responses were not generally associated with impact on nemolizumab exposure, safety, or efficacy.
In the Phase 3 Atopic Dermatitis pivotal trials (ARCADIA 1, ARCADIA 2) and ARCADIA LTE trial up to 128 weeks, the incidence of treatment-emergent ADAs was 11.2%; neutralizing antibodies were seen in 0.5% of subjects.
In the Phase 3 Prurigo Nodularis pivotal trials (OLYMPIA 1, OLYMPIA 2) and OLYMPIA LTE trial up to 116 weeks, the incidence of treatment-emergent ADAs was 12.8%; neutralizing antibodies were seen in 3.5% of subjects.
Paediatric population
Atopic dermatitis
Adolescents (12 to 17 years of age)
The safety of Nemluvio was assessed in 176 subjects 12 to 17 years of age with moderate-to-severe atopic dermatitis enrolled in the ARCADIA 1 and ARCADIA 2 trials. The safety profile of Nemluvio in these subjects through Week 16 was similar to the safety profile seen in adults with atopic dermatitis.
The safety profile of Nemluvio in adolescent subjects followed through Week 48 was similar to the safety profile observed at Week 16. The long-term safety profile of Nemluvio in subjects 12 to 17 years of age was consistent with that seen in adults with atopic dermatitis (ARCADIA LTE).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
There is no specific treatment for Nemluvio overdose. In the event of overdosage, monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Nemluvio 30 mg powder and solvent for solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.